Global Gynecology Partnering Report 2020: Access Deals Signed Between the World's Leading Pharmaceutical and Biotechnology Companies Since 2010

News provided by

Dec 23, 2020, 14:00 ET

DUBLIN, Dec. 23, 2020 /PRNewswire/ -- The "Global Gynecology Partnering 2010-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Global Gynecology Partnering 2010-2020: Deal trends, players and financials provides the full collection of Gynecology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Gynecology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gynecology deals.

The report presents financial deal terms values for Gynecology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In addition, a comprehensive appendix is provided with each report of all Gynecology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gynecology partnering and dealmaking since 2010.

The report includes deals for the following indications: Adenomyosis, Cervical Intraepithelial Neoplasia (CIN), Endometriosis, Fibroids, Human papillomavirus (HPV), Infertility, Menopause, Ovarian failure, Pelvic inflammatory disease, Polycystic ovary syndrome, Pre-menstrual syndrome, Prolapse, Amenorrhea, Dysmenorrhea, Pelvic pai, Vaginitis, plus other gynecological indications.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gynecology technologies and products.

Global Gynecology Partnering 2010 to 2020 includes:

Trends in Gynecology dealmaking in the biopharma industry since 2010
Analysis of Gynecology deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Gynecology deal contract documents
Comprehensive access to over 400 Gynecology deal records
The leading Gynecology deals by value since 2010
Most active Gynecology dealmakers since 2010

Available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in Gynecology dealmaking
2.1. Introduction
2.2. Gynecology partnering over the years
2.3. Gynecology partnering by deal type
2.4. Gynecology partnering by industry sector
2.5. Gynecology partnering by stage of development
2.6. Gynecology partnering by technology type
2.7. Gynecology partnering by therapeutic indication

Chapter 3 Financial deal terms for Gynecology partnering
3.1. Introduction
3.2. Disclosed financials terms for Gynecology partnering
3.3. Gynecology partnering headline values
3.4. Gynecology deal upfront payments
3.5. Gynecology deal milestone payments
3.6. Gynecology royalty rates

Chapter 4 Leading Gynecology deals and dealmakers
4.1. Introduction
4.2. Most active in Gynecology partnering
4.3. List of most active dealmakers in Gynecology
4.4. Top Gynecology deals by value

Chapter 5 Gynecology contract document directory
5.1. Introduction
5.2. Gynecology partnering deals where contract document available

Chapter 6 Gynecology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Gynecology therapeutic target

Appendices
Appendix 1 Directory of Gynecology deals by company A-Z 2010 to 2020
Appendix 2 Directory of Gynecology deals by deal type 2010 to 2020
Appendix 3 Directory of Gynecology deals by stage of development 2010 to 2020
Appendix 4 Directory of Gynecology deals by technology type 2010 to 2020

Companies Mentioned

23andMe
Abbvie
Accord Healthcare
Acerus
Advaxis
Adynxx
AEterna Zentaris
Agency for Healthcare Research and Quality
Agile Therapeutics
AirStrip Technologies
Albion
Allakos
Alvogen
American Dental Association
Amgen
Amos Gazit
ANI Pharmaceuticals
ApolloBio
Arbor Pharmaceuticals
Arc Medical Design
Ascend Therapeutics
ASKA Pharmaceuticals
Aspen Dental
ASPiRA Labs
AstraZeneca
Austrian Research Promotion Agency
Avion Pharmaceuticals
Aytu BioScience
Back Bay Scientific
Bavarian Nordic
Bayer
Bayer Healthcare
Baylor College of Medicine
Beckman Coulter
Beijing Genomics Institute (BGI)
Besins Healthcare
Bill and Melinda Gates Foundation
Biocon
Biomnis
Biotech Inc
BL&H
Bluebird Bio
BMV Medica
Boston Scientific
Bristol-Myers Squibb
California Institute for Biomedical Research
Celmatix
Center for Human Genetics and Laboratory Medicine
Chinese Academy of Sciences
Chun Fo Pharmaceutical
Cipla Medpro
ClearSpec
Clinigen
CNC Biotech
Co-Diagnostics
Cocrystal Pharma
CommonSense
Common Sense
Consortia Health
Control Flo Medical
Cooper Companies
Coriell Life Sciences
CR Pharma
CVC Capital Partners
Cynosure
Debiopharm
DIAsource ImmunoAssays
Dilafor
Distal Access
Duchesnay
Duke University
DySIS Medical
Easton Pharmaceuticals
Egalet
El.En
Elanix Biotechnologies
EMD Serono
Emory University
EndoCeutics
European Board and College of Obstetrics and Gynaecology
European Organization for Research and Treatment of Cancer
European Union Regional Development Fund
Evestra
Evotec
Expedeon
Famy Care
Ferring Pharmaceuticals
Flo Health
Fogarty Institute for Innovation
Foresee Pharmaceuticals
Fougera Pharmaceuticals
Fuji Pharma
Genea Biomedx
Genoma
Genome Medical
German Cancer Research Center
Gilead Sciences
GlaxoSmithKline
GOG Foundation
Golden Valley Development
Good Start Genetics
Grunenthal
Guided Therapeutics
Gynica
Halt Medical
Hammock Pharmaceuticals
HealthNet
Helix
Helix BioPharma
Hologic
Hookipa Biotech
Hope Medicine
HTG Molecular Diagnostics
Igantia Therapeutics
iGenomix
Illumina
Imaxio
IncellDx
InnerOptic Technology
Innovus Pharmaceuticals
Inovio Pharmaceuticals
Intuitive Surgical
INVO Bioscience
Irvine Scientific
IsoRay
ITEM Medical Technologies
IviGen
Janssen Pharmaceuticals
Johns Hopkins University
Joylux
Karolinska Institute
Kissei Pharmaceutical
Kite Pharma
Knight Therapeutics
Kyoto University
Laboratory Corporation of America
Laccure
Lake Consumer Products
Lee's Pharmaceutical
LFB Biotechnologies
LifeCodexx
Lumara Health
Lumir Lab
Massachusetts General Hospital
McKesson
MD Anderson Cancer Center
MDNA Life Sciences
Meda
MEDCIS Pathlabs
Medical University of South Carolina
Medical University South Carolina
MediCare International
MediGene
MedikorPharma
MedImmune
Medinova
MedTech For Solutions
Medtronic
Mel-Mont Medical
MenoGeniX
Merck and Co
Merck KGaA
Merck Serono
Merus Labs International
MilanaPharm
Millendo Therapeutics
Ministry of Health (Turkey)
Mission Pharmacal
Mithra Pharmaceuticals
Mitsubishi Tanabe Pharma
Morphic Therapeutic
MSD
Mundipharma
MyBiotics Pharma
Mylan Laboratories
Myovant Sciences
Myrtle Potter & Company
Naka International
Natera
National Institute for Public Health and the Environment
National Institute on Aging
National Institutes of Health
Neoteric Technology
NextGen LifeLabs
Nobelpharma
Norgine
Northwestern University
Novation
Noven Pharmaceuticals
Novogene
NX Prenatal
OBP Medical
ObsEva
Olympus
OncoSec Medical
Oncotest
Oral Cancer Foundation
OvaGene Oncology
Oxford MEstar
Patient-Centered Primary Care Collaborative (PCPCC)
PaxGenBio
PCOS Challenge
PCOS Diva
PDS Biotechnology
Peking University
Perinatal Quality Foundation
PerkinElmer
Perrigo
Pfizer
PharmaJet
Pharmanest
Pharma Solutions Peru
Psyche Systems
Radius Health
Rebiotix
Recipharm
Reproductive Health Science
Reprogenetics
rEVO Biologics
Roche
Romark Laboratories
Royal Philips Electronics
Sanofi
Sanofi-Pasteur
Scholar Rock
Selecta Biosciences
Shandong Yaohua Medical Instrument
Shenghuo Medical
Shionogi
Shire Pharmaceuticals
Sims IVF
Sincopharm
Sirio Pharma
Skolkovo Foundation
Smith & Nephew
Smiths Medical
Society For Reproductive Investigation
Society of Gynecologic Oncology
SRI International
Starpharma
Strainprint Technologies
Sun Pharmaceutical
Surgicorp
Syn-The-All Pharmaceutical
SynteractHCR
Takeda Pharmaceutical
Tec-Pharma
Telenatal
Tesaro
Tessa Therapeutics
Teva Pharmaceutical Industries
Teva Pharmaceuticals USA
Theramex
TherapeuticsMD
Thermo Fisher Scientific
Transgene
Trimel Pharmaceuticals
Trivector Biomed
Trophogen
twoXAR
Unified Women's Clinical Research
University College Dublin Conway Institute
University Magna Graecia
University of Hong Kong
University of Michigan
University of Oxford
University of Siena
Upsher-Smith
Vaccibody
Valeo Pharma
Vertical Pharmaceuticals
Viramal
Virtus Health
VolitionRX
Wayne State University
Wellmed
Windsor Pharmaceuticals
Womens Choice Pharmaceuticals
Wuxi Apptec Laboratory Services
Xbrane Bioscience
Xisle Pharma Ventures Trust
ZenTech
Zhengzhou University
Zoetis

For more information about this report visit https://www.researchandmarkets.com/r/9ex5qc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets